Key Drivers
- Strong liquidity
- Zero revenue
- High cash burn
AIAI Summary
Sionna has shifted from a cash‑burn speculative biotech to a funded, event‑driven investment—with a multi‑year runway and clustered mid‑2026 SION‑719/SION‑451 readouts that could materially re‑rate the stock, but the key action is to monitor those toplines and quarterly burn guidance closely since negative/ambiguous results or rising spend would quickly force dilution or repricing.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Zero revenue
- •High cash burn
SION has abundant liquid assets and almost no debt but is unprofitable with zero revenue and high cash burn driven by opex/R&D, leaving cash to cover less than a year of losses despite a rich market valuation.
Price Behavior
Key Price Behavior Insights:
- •Above last month
- •RSI ~60
- •Repeated failed highs
SION shows a mild short-term upside bias—price sits just above its last month average with RSI ~60, clear support in the mid-$30s and resistance near the high-$38s, so a volume-confirmed break above ~$38 would confirm stronger upside while the mid-$30s serves as nearby risk control.
Gap from higher
Sentiment & News
Key News Insights:
- •Share-price rally
- •Institutional churn
- •Cash runway
Sionna shares have surged amid mixed institutional trading while the company reports a ~$310M cash runway into 2028 and on‑track mid‑2026 clinical readouts for SION-719 and combos.
Strong cash and upcoming clinical readouts make SION a high-upside, high-volatility name driven by near-term trial results
Similar Companies in Healthcare
Other companies in the same sector with AI ratings